CompletedNot Applicable

Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs

Egypt42 participantsStarted 2018-07-01

Plain-language summary

Case control Study to assess the difference of immune cell responses between patients with chronic HCV- related liver cirrhosis who develop HCC after treatment with DAAs and those who do not develop HCC

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with HCC on top of HCV related liver cirrhosis either received treatment or not * Patients without HCC either received treatment or not . * Patients with chronic HCV as a control group either received treatment or not. Exclusion Criteria: * Patients with HCC who received any interventional treatment as alcohol injection, radiofrequency , TACE..etc * Patients with recurrent HCC after curative treatment.

What they're measuring

Pattern of immunity in patients with de novo HCC develped after treatment with DAAs

Timeframe: Two months

Trial details

NCT IDNCT03602703

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-09-01

View on ClinicalTrials.gov More Drug-Induced Liver Injury trials